Last updated: February 27, 2026
What is the Drug and Its Market Context?
NDC 46122-0572 corresponds to Atezolizumab (Tecentriq), a monoclonal antibody used for cancer immunotherapy. Approved by the FDA for multiple indications, including non-small cell lung cancer, urothelial carcinoma, and small cell lung cancer, Tecentriq has established a substantial presence in oncology treatments.
Current Market Position (as of 2023)
| Data Point |
Details |
| Therapeutic Area |
Oncology (lung, bladder, breast) |
| Approved Indications |
NSCLC, metastatic urothelial carcinoma, triple-negative breast cancer, other solid tumors |
| Peak Sales (2022) |
Approx. $4.4 billion (IQVIA) |
| Market Share (2023) |
Estimated 40% in PD-L1 inhibitors for NSCLC |
Market Drivers
- Rising prevalence of lung and bladder cancers globally.
- Expansion of indications, including early-stage and adjuvant settings.
- Growing adoption of immunotherapy as first-line treatment.
- Competitive combination therapies with chemo and targeted agents.
Competitive Landscape
| Competitors |
Market Shares (2023) |
Key Features |
| Pembrolizumab (Keytruda) |
55% |
Broader approval, higher sales |
| Atezolizumab (Tecentriq) |
40% |
First PD-L1 inhibitor approved, expanding indications |
| Durvalumab (Imfinzi) |
20% |
Approved for stage III NSCLC and other tumors |
(Note: Market shares are estimates based on sales data and prescription volumes.)
Price Analysis
Current Pricing Environment
- List Price per Dose: Approx. $10,000 – $13,000 (based on a 1,200 mg dose administered every 3 weeks).
- Average Treatment Cost: $150,000 – $200,000 per year, depending on indication and dosing schedules.
- Reimbursement Environment: Managed through negotiated payer contracts, with considerable discounts and rebates affecting net prices.
Price Trends
| Time Frame |
Price Changes |
Notes |
| 2019 |
Stable |
List prices remained consistent upon launch. |
| 2020 |
Slight increase (~2%) |
Due to inflation and manufacturing costs. |
| 2021–2022 |
No significant change |
Payer negotiations maintained price stability. |
| 2023 |
Potential increase (~3%) |
Expected, based on inflation and expanded labeling. |
Pricing Comparison
| Agent |
List Price per Dose |
Yearly Treatment Cost |
Indications |
| Tecentriq (Atezolizumab) |
$12,500 |
~$180,000 |
NSCLC, bladder, breast |
| Keytruda (Pembrolizumab) |
$13,000 |
~$200,000 |
Broad, leading first-line presence |
| Imfinzi (Durvalumab) |
$11,500 |
~$160,000 |
Stage III NSCLC |
Future Price Projections
Factors Influencing Price Trajectory:
- Regulatory Approval Expansion: Additional indications could lead to increased dosage and higher costs.
- Payer Negotiations: Increased pressure for discounts could stabilize or slightly lower prices.
- Market Competition: Intensified competition from emerging PD-L1/L1 inhibitors may trigger price reductions.
Projected Price Range (Next 3 Years):
| Year |
Expected List Price per Dose |
Approximate Annual Treatment Cost |
Notes |
| 2024 |
$12,750 |
~$185,000 |
Market stabilization |
| 2025 |
$13,000 |
~$190,000 |
Slight increase for expanded use |
| 2026 |
$13,250 |
~$195,000 |
Competitive pressures may moderate growth |
Summary
Atezolizumab (NDC 46122-0572) faces a robust but competitive market landscape. Its sales depend heavily on expanding indications and payer negotiations. The price per dose is expected to increase gradually, influenced by regulatory approvals and market dynamics.
Key Takeaways
- Tecentriq remains a leading PD-L1 inhibitor with around 40% market share in its category.
- List prices have remained relatively stable since launch, with minor annual increases.
- The drug's annual treatment cost hovers around $180,000, with slight upward adjustments projected.
- Competition from pembrolizumab and durvalumab influences pricing strategies and market share.
- Future price growth will depend on expansion of indications, regulatory support, and payer negotiations.
FAQs
1. How does Tecentriq’s pricing compare to other PD-L1 inhibitors?
Tecentriq’s per-dose list price is slightly below pembrolizumab but higher than durvalumab; overall treatment costs show similar margins when factoring in dosing schedules.
2. What factors could lead to lower prices in the future?
Increased competition, broader payer discounts, and pipeline biosimilars may exert downward pressure.
3. Will new indications significantly impact Tecentriq pricing?
Potentially, if approvals lead to extended treatment durations or higher doses, increasing overall treatment costs.
4. How does the reimbursement environment affect Tecentriq’s net pricing?
Rebate agreements and negotiated discounts considerably lower the actual net price paid by healthcare providers.
5. Are biosimilars expected for Tecentriq?
Currently, no biosimilars are approved, but market entry could alter future pricing dynamics.
References
- IQVIA. (2023). Pharmaceutical Sales Data.
- FDA. (2021). Atezolizumab (Tecentriq) Approval Summary.
- EvaluatePharma. (2023). Oncology Market Outlook.
- Centers for Medicare & Medicaid Services (CMS). (2023). Reimbursement Data.
- MarketWatch. (2023). Biotech Pricing Trends.
